There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil) will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed surgery and radiotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
University of Arkansas
Little Rock, Arkansas, United States
RECRUITINGUnversity of Colorado Cancer Center
Aurora, Colorado, United States
RECRUITINGUniversity of Miami Hospital and Sylvester Comprehensive Cancer Center
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Miami, Florida, United States
Norton Healthcare Pavilion
Louisville, Kentucky, United States
RECRUITINGCenter Center of GBMC
Baltimore, Maryland, United States
RECRUITINGWJB Dorn VA Medical Center
Columbia, South Carolina, United States
RECRUITINGMary Crowley Medical Research Center
Dallas, Texas, United States
RECRUITINGUniversity of Texas, MD Andersen Cancer Center
Houston, Texas, United States
RECRUITING